K-ras基因与结直肠癌疗效

国际肿瘤学杂志››2014,Vol. 41››Issue (3): 214-216.doi:10.3760/cma.j.issn.1673-422X.2014.01.017

于法常, 李胜, 牛作兴

250062济南大学 betway.com 医学与生命科学学院

出版日期:2014-03-08发布日期:2014-03-17
通讯作者:牛作兴，E-mail：nzxsdth@163.com E-mail:nzxsdth@163.com

K-ras gene and colorectal cancer therapeutic effect

YU Fa-Chang, LI Sheng, NIU Zuo-Xing

Ji’nan University Shandong Academy of Medical Sciences Medicine and Life Science; Department of Medicine, Shandong Cancer Hospital, Ji′nan 250062, China

Online:2014-03-08Published:2014-03-17
Contact:Niu Zuoxing, E-mail: nzxsdth@163.com E-mail:nzxsdth@163.com

摘要/Abstract

摘要：K-ras基因是一种癌基因，促进细胞生长、分化，基因的突变使ras蛋白丧失GTP酶活性，导致细胞的异常生长、分化，促进癌的发生，同时导致使用抗表皮生长因子受体（EGFR）多克隆抗体药物治疗的结直肠癌患者无明显获益。结直肠癌不同实体肿瘤的K-ras基因突变率不同，K-ras基因野生型或突变型对治疗方案选择及预后具有重要意义，突变型患者使用抗EGFR抗体治疗效果差，对5-FU、FOLFOX疗效尚无一致定论。

关键词:结直肠肿瘤,治疗结果,K-ras基因

Abstract:K-ras gene is one of oncogenes, which promotes cells growth and differentiation. Ras protein loses the activity of GTP enzyme because of K-ras mutations, and that may cause abnormal growth, differentiation of cells and promote the occurrence of tumor. Patients with colorectal carcinoma that carry mutations in K-ras gene do not benefit from the administration of antiepidermal growth factor receptor (EGFR) polyclonal antibodies. Different solid tumors of colorectal carcinoma have different K-ras mutation rates. Different genotypes of K-ras gene (wildtype or K-ras mutant type) affect significantly on treatment options and prognosis. The efficacy of mutant type patients with antiEGFR antibodies is poor, and the therapeutic effects of 5-FU and FOLFOX are still unclear.

Key words:Colorectal neoplasms,Treatment outcome,K-ras gene

于法常, 李胜, 牛作兴. K-ras基因与结直肠癌疗效[J]. 国际肿瘤学杂志, 2014, 41(3): 214-216.

YU Fa-Chang, LI Sheng, NIU Zuo-Xing. K-ras gene and colorectal cancer therapeutic effect[J]. Journal of International Oncology, 2014, 41(3): 214-216.

参考文献

［1］ Navas C, HernándezPorras I, Schuhmacher AJ, et al. EGF receptor signaling is essential for kras oncogenedriven pancreatic ductal adenocarcinoma［J］. Cancer Cell, 2012, 22(3):318330. ［2］ Sebio A, Paré L, Páez D, et al. The LCS6 polymorphism in the binding site of let7 microRNA to the KRAS 3′untranslated region: its role in the efficacy of antiEGFRbased therapy in metastatic colorectal cancer patients［J］. Pharmacogenet Genomics, 2013, 23(3):142147. ［3］ Troiani T, Zappavigna S, Martinelli E, et al. Optimizing treatment of metastatic colorectal cancer patients with antiEGFR antibodies: overcoming the mechanisms of cancer cell resistance［J］. Expert Opin Biol Ther, 2013, 13(2):241255. ［4］ Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic kRAS mutations as a mechanism associated with resistance to EGFRtargeted agents: a systematic review and metaanalysis of studies in advanced nonsmallcell lung cancer and metastatic colorectal cancer［J］. Lancet Oncol, 2008, 9(10):962972. ［5］ Bach LA, Fu P, Yang Z. Insulinlike growth factorbinding protein6 and cancer［J］. Clin Sci (Lond), 2013, 124(4):215229. ［6］ Ramos FJ, Macarulla T, Capdevila J, et al. Understanding the predictive role of Kras for epidermal growth factor receptortargeted therapies in colorectal cancer［J］. Clin Colorectal Cancer, 2008, 7 Suppl 2:S5257. ［7］ Karapetis CS, KhambataFord S, Jonker DJ, et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer［J］. N Engl J Med, 2008, 359(17):17571765. ［8］ De Roock W, Piessevaux H, De Schutter J, et al. KRAS wildtype state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab［J］. Ann Oncol, 2008, 19(3):508515. ［9］ Dempke WC, Heinemann V. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma［J］. Anticancer Res, 2010, 30(11):46734677. ［10］ Phipps AI, Buchanan DD, Makar KW, et al. KRASmutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers［J］. Br J Cancer, 2013, 108(8):17571764. ［11］ Chen X, Guo X, Zhang H, et al. Role of miR143 targeting KRAS in colorectal tumorigenesis［J］. Oncogene, 2009, 28(10):13851392. ［12］ Borralho PM, Kren BT, Castro RE, et al. MicroRNA143 reduces viability and increases sensitivity to 5fluorouracil in HCT116 human colorectal cancer cells［J］. FEBS J, 2009, 276(22):66896700. ［13］ Bengala C, Bettelli S, Bertolini F, et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy［J］. Br J Cancer, 2010, 103(7):10191024. ［14］ Van Cutsem E, Khne CH, Lng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status［J］. J Clin Oncol, 2011, 29(15):20112019. ［15］ Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX4 as firstline treatment for metastatic colorectal cancer: the OPUS study［J］. Ann Oncol, 2011, 22(7):15351546. ［16］ Commisso C, Davidson SM, SoydanerAzeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Rastransformed cells［J］. Nature, 2013, 497(7451):633637. ［17］ Chang MH, Lee IK, Si Y, et al. Clinical impact of Kras mutation in colorectal cancer patients treated with adjuvant FOLFOX［J］. Cancer Chemother Pharmacol, 2011, 68(2):317323.